Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Glycomimetics Inc (GLYC)

Glycomimetics Inc (GLYC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,196
  • Shares Outstanding, K 52,424
  • Annual Sales, $ 1,160 K
  • Annual Income, $ -63,430 K
  • 60-Month Beta 2.42
  • Price/Sales 109.82
  • Price/Cash Flow N/A
  • Price/Book 2.65
Trade GLYC with:

Options Overview Details

View History
  • Implied Volatility 365.03% ( +204.08%)
  • Historical Volatility 133.63%
  • IV Percentile 81%
  • IV Rank 26.29%
  • IV High 1,222.59% on 09/20/22
  • IV Low 59.12% on 03/18/22
  • Put/Call Vol Ratio 0.01
  • Today's Volume 176
  • Volume Avg (30-Day) 680
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 12,429
  • Open Int (30-Day) 9,494

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.16
  • Low Estimate -0.31
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +36.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.82 +152.38%
on 11/10/22
2.51 -17.53%
on 12/07/22
+1.25 (+152.38%)
since 11/09/22
3-Month
0.55 +276.36%
on 10/03/22
2.51 -17.53%
on 12/07/22
+1.34 (+183.56%)
since 09/09/22
52-Week
0.51 +305.88%
on 06/16/22
2.51 -17.53%
on 12/07/22
+0.43 (+26.22%)
since 12/09/21

Most Recent Stories

More News
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?

Here is how GlycoMimetics (GLYC) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

GLYC : 2.07 (-11.91%)
AXNX : 64.43 (-2.22%)
After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

GLYC : 2.07 (-11.91%)
Are Medical Stocks Lagging Axonics (AXNX) This Year?

Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.

AXNX : 64.43 (-2.22%)
GLYC : 2.07 (-11.91%)
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 2.07 (-11.91%)
GlycoMimetics to Participate in Two Upcoming Investor Conferences

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that management will participate in two upcoming investor conferences.

GLYC : 2.07 (-11.91%)
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that data...

GLYC : 2.07 (-11.91%)
GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter financial results on Wednesday, November 9, 2022, at 8:30 a.m. ET.

GLYC : 2.07 (-11.91%)
GlycoMimetics (GLYC) Upgraded to Buy: Here's Why

GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GLYC : 2.07 (-11.91%)
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlycoMimetics, Inc. (the “ Company ”) (NASDAQ:GLYC) today announced that the compensation committee of the Company’s Board of Directors approved the grant on September 2, 2022 of a non-qualified...

GLYC : 2.07 (-11.91%)
GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24 th Annual Global Investment Conference in New York,...

GLYC : 2.07 (-11.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at...

See More

Key Turning Points

3rd Resistance Point 2.57
2nd Resistance Point 2.46
1st Resistance Point 2.26
Last Price 2.07
1st Support Level 1.95
2nd Support Level 1.84
3rd Support Level 1.64

See More

52-Week High 2.51
Last Price 2.07
Fibonacci 61.8% 1.75
Fibonacci 50% 1.51
Fibonacci 38.2% 1.27
52-Week Low 0.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar